Recently it was suggested that PRMT5-induced epigenetic regulation may activate the expression of MYC [111–113] and MYB [28, 96] (the key molecular drivers of ACC progression) [96–98], further supporting its role as putative therapeutic candidate for ACC. This evidence concerns the gene PRMT5 and adrenal cortex carcinoma.